MTHRF - M3, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
23.60
0.00 (0.00%)
At close: 10:43AM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close23.60
Open23.70
BidN/A x N/A
AskN/A x N/A
Day's Range23.60 - 23.60
52 Week Range23.60 - 35.18
Volume3,100
Avg. Volume1,119
Market Cap16.023B
Beta (5Y Monthly)0.88
PE Ratio (TTM)48.16
EPS (TTM)0.49
Earnings DateN/A
Forward Dividend & Yield0.26 (1.11%)
Ex-Dividend DateMar 30, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MTHRF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PR Newswire

    M3 WAKE RESEARCH POISED TO EXPAND PHASE I TRIAL SERVICES

    M3 Wake Research, a leading fully integrated network of clinical research sites and one of North America's largest providers of Phase I-IV clinical trials, announces the appointment of a new executive role to lead and grow Phase I Operations. Lucian Cappoli will serve as Head of Early Development and Phase I Operations. Since joining M3 Wake Research in 2019, Cappoli has led commercial business contracting for the clinical research network. He brings an extensive background in Phase I clinical r